TaiMed Biologics Inc. (TPEX: 4147)

Market Cap	21.81B
Revenue (ttm)	641.66M
Net Income (ttm)	-109.74M
Shares Out	273.01M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	49.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	325,956
Open	80.90
Previous Close	80.60
Day's Range	79.50 - 81.00
52-Week Range	66.60 - 116.50
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4147

Financial Performance

In 2023, TaiMed Biologics's revenue was 491.78 million, a decrease of -12.65% compared to the previous year's 563.01 million. Losses were -194.81 million, -27.66% less than in 2022.